Research output per year
Research output per year
Personal profile
Research interests
Leukemia, stem cell mobilization, glioblastoma
Areas of Clinical Interest
Leukemia, MDS, brain tumors, melanoma oncology
Fingerprint
Dive into the research topics where George Ansstas is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
BRAF-MEK inhibitors as steroid-sparing bridge prior to checkpoint blockade therapy in symptomatic intracranial melanoma
Khaddour, K., Johanns, T. M. & Ansstas, G., Jun 2021, In: Melanoma Management. 8, 2, 0022.Research output: Contribution to journal › Article › peer-review
Open Access -
Durable remission after rechallenge with ipilimumab and nivolumab in metastatic Merkel cell carcinoma refractory to avelumab: Any role for sequential immunotherapy?
Khaddour, K., Rosman, I. S., Dehdashti, F. & Ansstas, G., Feb 2021, In: Journal of Dermatology. 48, 2, p. e80-e81Research output: Contribution to journal › Letter › peer-review
3 Scopus citations -
Mutation clearance and complete radiologic resolution of immunotherapy relapsed metastatic melanoma after treatment with nivolumab and olaparib in a patient with homologous recombinant deficiency: any role for PARP inhibitors and checkpoint blockade?
Khaddour, K., Ansstas, M., Visconti, J. & Ansstas, G., Feb 2021, In: Annals of Oncology. 32, 2, p. 279-280 2 p.Research output: Contribution to journal › Letter › peer-review
1 Scopus citations -
Normalization of electroretinogram and symptom resolution of melanoma-associated retinopathy with negative autoantibodies after treatment with programmed death-1 (PD-1) inhibitors for metastatic melanoma
Khaddour, K., Khanna, S., Ansstas, M., Jakhar, I., Dahiya, S., Council, L. & Ansstas, G., Sep 2021, In: Cancer Immunology, Immunotherapy. 70, 9, p. 2497-2502 6 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Successful administration of sequential TVEC and pembrolizumab followed by temozolomide in immunotherapy refractory intracranial metastatic melanoma with acquired B2M mutation
Khaddour, K., Dowling, J., Huang, J., Council, M., Chen, D., Cornelius, L., Johanns, T., Dahiya, S. & Ansstas, G., 2021, In: Oncotarget. 11, 35, p. 4836-4844 9 p.Research output: Contribution to journal › Article › peer-review
Open Access